Neureliv 50
100.00৳ Strip(10)
- Neureliv is an aldose reductase inhibitor used to manage symptoms of diabetic peripheral neuropathy, including numbness, pain, and abnormal heartbeat.
- It works by inhibiting aldose reductase, preventing sorbitol accumulation in nerves, and improving nerve function.
- The recommended dose is 50 mg, three times daily before meals, adjusted based on the patient’s condition.
- Neureliv should be used under the guidance of a healthcare professional, especially for patients with high glycohemoglobin levels.
Brand
|
Incepta Pharmaceuticals Ltd |
|---|---|
Generics
|
Epalrestat |
Type
|
Tablet |
Indications
Neureliv is used to alleviate the subjective symptoms of diabetic peripheral neuropathy, including numbness, pain, altered vibration sense, and irregular heartbeat, especially when high glycohemoglobin levels are present.
Use as per the advice of a registered healthcare professional.
Pharmacology
Neureliv contains epalrestat, which selectively inhibits aldose reductase, preventing the accumulation of sorbitol in the nerves. This helps to improve the nerve function and reduce symptoms of diabetic peripheral neuropathy.
Dosage & Administration
The recommended dosage for adults is one 50 mg tablet three times a day, taken before meals. The dosage may be adjusted based on the patient’s age and symptoms.
Use as directed by a registered healthcare professional.
Drug Interactions
Currently, there are no known significant drug interactions with Neureliv.
Contraindications
Neureliv should not be used by individuals who are hypersensitive to epalrestat.
Side Effects
Possible side effects include hepatic function abnormalities and thrombocytopenia. If hepatic dysfunction occurs, discontinue the medication immediately and take appropriate action. Other side effects may include malaise, headache, abdominal discomfort, nausea, and allergic reactions.
Pregnancy & Lactation
The safety of Neureliv during pregnancy has not been established. It should only be used during pregnancy if the potential benefits outweigh the risks. It is not recommended during breastfeeding.
Precautions & Warnings
Neureliv should be considered for use in patients with high glycohemoglobin levels despite receiving standard diabetes management, including diet, exercise, and medications like insulin or oral hypoglycemics. Its effectiveness in patients with irreversible nerve damage due to diabetic peripheral neuropathy has not been established. Continuous monitoring is advised during treatment. If there is no improvement after 12 weeks, alternative treatments should be considered.
Therapeutic Class
Aldose Reductase Inhibitor
Storage Conditions
Store Neureliv below 30°C, away from light and moisture. Keep it out of reach of children.
Reviews
There are no reviews yet.